AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing ...

This deal adds two more siRNA candidates to GSK’s pipeline, which is expanding as the company looks to offset the impact of ...

The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new framework to spur the development of therapies for ultra-rare ...

Beren Therapeutics has received the US (FDA acceptance to review its NDA for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset NPC.

Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.

Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) to enhance pharmaceutical education and research ...

Three new members could join Novo’s council, which largely consists of recent appointees following a restructure in October ...

The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.

J&J's Pennsylvania cell therapy manufacturing site is one of four US-based facilities the company plans to build over the ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

Following a difficult year that saw Ixchiq’s license suspended in the US, Valneva is pinning hopes on upcoming pipeline ...

AstraZeneca has secured approval in the US for Calquence plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with CLL and SLL in the first-line setting.